- Home
- DCOM vs COLL Comparison
DCOM vs COLL Comparison
Compare DCOM & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- COLL
- Stock Information
- Founded
- DCOM 1864
- COLL 2002
- Country
- DCOM United States
- COLL United States
- Employees
- DCOM N/A
- COLL N/A
- Industry
- DCOM Major Banks
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- COLL Health Care
- Exchange
- DCOM Nasdaq
- COLL Nasdaq
- Market Cap
- DCOM 1.2B
- COLL 1.1B
- IPO Year
- DCOM 1996
- COLL 2015
- Fundamental
- Price
- DCOM $33.70
- COLL $29.58
- Analyst Decision
- DCOM Strong Buy
- COLL Strong Buy
- Analyst Count
- DCOM 5
- COLL 6
- Target Price
- DCOM $29.60
- COLL $42.00
- AVG Volume (30 Days)
- DCOM 317.3K
- COLL 440.1K
- Earning Date
- DCOM 10-22-2024
- COLL 11-07-2024
- Dividend Yield
- DCOM 2.97%
- COLL N/A
- EPS Growth
- DCOM N/A
- COLL 757.11
- EPS
- DCOM 1.50
- COLL 2.16
- Revenue
- DCOM $313,737,000.00
- COLL $599,245,000.00
- Revenue This Year
- DCOM N/A
- COLL $13.02
- Revenue Next Year
- DCOM $23.85
- COLL $18.01
- P/E Ratio
- DCOM $22.46
- COLL $13.68
- Revenue Growth
- DCOM N/A
- COLL 9.62
- 52 Week Low
- DCOM $17.29
- COLL $25.07
- 52 Week High
- DCOM $35.21
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- DCOM 62.70
- COLL 26.96
- Support Level
- DCOM $33.31
- COLL $29.69
- Resistance Level
- DCOM $34.72
- COLL $35.62
- Average True Range (ATR)
- DCOM 1.18
- COLL 1.41
- MACD
- DCOM 0.15
- COLL -0.39
- Stochastic Oscillator
- DCOM 75.37
- COLL 6.36
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.